Want to see PHR full AI Analyst Report?
PHR Stock Chart & Stats
$9.17
$0.87(3.22%)
At close: 4:00 PM EST
$9.17
$0.87(3.22%)
Day’s Range― - ―
52-Week Range$7.77 - $32.76
Previous CloseN/A
Volume173.69K
Average Volume (3M)1.15M
Market Cap
$663.86M
Enterprise Value$595.79M
Total Cash (Recent Filing)$74.71M
Total Debt (Recent Filing)$92.56M
Price to Earnings (P/E)70.7
Beta1.00
Next Earnings
Sep 09, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding61,811,890
10 Day Avg. Volume764,983
30 Day Avg. Volume1,149,162
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)2.38
Price to Sales (P/S)1.67
P/FCF Ratio11.85
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue1.20
Enterprise Value/Gross Profit1.83
Enterprise Value/Ebitda14.04
Forecast
1Y Price Target
$14.00Price Target Upside52.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)0.4
Revenue Forecast (FY)$515.18M
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained operating and free cash flow conversion provides durable internal financing capacity. With FCF at ~86% of net income and year-over-year FCF growth, Phreesia can fund product investment, pay down debt or finance Access One integration without relying on equity markets, supporting stability over months.
Profitability Inflection And EBITDA ExpansionA clear move to sustained adjusted EBITDA expansion and consecutive quarters of positive net income demonstrates operating leverage and improved cost discipline. This structural margin improvement underpins long-term cash generation and makes the business less sensitive to modest revenue slowdowns.
Enhanced Liquidity And Funding FlexibilityLarger, longer-tenor credit facilities and an expanded receivables securitization materially improve near-term liquidity and funding for payment products. This structural financing capacity supports growth in Payment Solutions and provides runway to execute strategy without immediate refinancing pressure.
Bears Say
Subscription Revenue SoftnessSubscription fees are the core recurring provider revenue; a sequential 6% decline signals retention or pricing pressure. If sustained, lower subscription traction would erode predictable recurring revenue and reduce the base for upsells, making long-term growth and margin targets harder to sustain.
Network Solutions Demand VariabilityHigher variability and weaker client commitments in Network Solutions reduce revenue visibility and make multi-quarter planning difficult. Because life-sciences campaign revenue depends on client commitments, sustained variability can compress growth, complicate capacity allocation, and increase forecast risk.
Securitization Concentration & Contingent LiabilityRaising concentration limits and becoming joint guarantor materially increases Phreesia's contingent credit exposure on receivables. Structurally this enhances funding flexibility but also amplifies downside balance-sheet risk if provider payment performance deteriorates or lower‑rated receivables stress the pool.
Phreesia News
PHR FAQ
What was Phreesia’s price range in the past 12 months?
Phreesia lowest stock price was $7.77 and its highest was $32.76 in the past 12 months.
What is Phreesia’s market cap?
Phreesia’s market cap is $663.86M.
When is Phreesia’s upcoming earnings report date?
Phreesia’s upcoming earnings report date is Sep 09, 2026 which is in 55 days.
How were Phreesia’s earnings last quarter?
Phreesia released its earnings results on May 27, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.011 by $0.039.
Is Phreesia overvalued?
According to Wall Street analysts Phreesia’s price is currently Undervalued.
Does Phreesia pay dividends?
Phreesia does not currently pay dividends.
What is Phreesia’s EPS estimate?
Phreesia’s EPS estimate is 0.09.
How many shares outstanding does Phreesia have?
Phreesia has 61,811,890 shares outstanding.
What happened to Phreesia’s price movement after its last earnings report?
Phreesia reported an EPS of $0.05 in its last earnings report, beating expectations of $0.011. Following the earnings report the stock price went up 3.505%.
Which hedge fund is a major shareholder of Phreesia?
Currently, no hedge funds are holding shares in PHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phreesia Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (52.67% Upside)
$14.00 (52.67% Upside)
Blogger Sentiment
Neutral
PHR Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.74%
12-Months-Change
Fundamentals
Return on Equity
2.79%
Trailing 12-Months
Asset Growth
66.37%
Trailing 12-Months
Company Description
Phreesia
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
PHR Revenue Breakdown
45.91% Subscription and related services
27.90% Payment processing fees
26.19% Network solutions
PHR Stock 12 Month Forecast
Average Price Target
$14.00
▲(52.67% Upside)
Technical Analysis
Ownership Overview
20.63% Insiders
18.24% Mutual Funds
35.52% Other Institutional Investors
13.57% Public Companies and
Individual Investors